Ahmed Zikri

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

Patrick N. A. Harris, Paul Anantharajah Tambyah, David Chien Lye et al. · JAMA · 2018 · 770 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study

Andrew Henderson, David L. Paterson, Mark D. Chatfield et al. · Clinical Infectious Diseases · 2020 · 158 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Prevalence of infections and antimicrobial use in the acute-care hospital setting in the Middle East: Results from the first point-prevalence survey in the region

Adel Alothman, Abdulhakeem Al Thaqafi, Adel Al Ansary et al. · International Journal of Infectious Diseases · 2020 · 29 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia

Ahmed Zikri, Kamal El Masri · Antibiotics · 2019 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infections: Post Hoc Insights From the MERINO Trial

Melissa J. Hardy, Patrick N. A. Harris, David L. Paterson et al. · Clinical Infectious Diseases · 2024 · 12 citations · Full text

Pharmacy, Biostatistics, Infectious Diseases +16